SPRR1B: A Potential Drug Target and Biomarker (G6699)

Target Name: SPRR1B

NCBI ID: G6699

SPRR1B

SPRR1B: A Potential Drug Target and Biomarker

Sprr1b, also known as SPR-IB, is a protein that is expressed in the brain and is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. The study of synaptic plasticity has been ongoing for several decades, and recent advances in the field have identified SPRR1b as a potential drug target and biomarker.

SPRR1b is a transmembrane protein that is characterized by a unique arrangement of its transmembrane domains. It consists of an N-terminal cytoplasmic domain, a transmembrane region, and an C-terminal protein domain that includes a putative nuclear localization region and a series of putative transmembrane interacts. SPRR1b is highly expressed in the brain and is involved in the regulation of various cellular processes that are critical for brain development, function, and disease.

One of the key functions of SPRR1b is its role in synaptic plasticity. SPRR1b is involved in the regulation of the formation and stability of synapses, which are the structural and functional units of the brain's neural network. It does this by participating in various signaling pathways that regulate the activity of neurons and glial cells, which are support cells for neurons.

SPRR1b is also involved in the regulation of neurotransmitter release and cell survival. It has been shown to play a role in the regulation of the release of neurotransmitters such as dopamine and synaptophysin, which are involved in the transmission of signals in the brain. SPRR1b has also been shown to be involved in the regulation of cell survival, as it has been shown to play a role in the apoptosis, or programmed cell death, of neurons.

In addition to its role in synaptic plasticity, SPRR1b is also a potential biomarker for various neurological and psychiatric disorders. For example, studies have shown that SPRR1b is involved in the regulation of the formation and stability of synapses in the brain, which may be involved in the development of Alzheimer's disease. Additionally, SPRR1b has been shown to be involved in the regulation of neurotransmitter release, which may be involved in the development of Parkinson's disease.

SPRR1b is also a potential drug target, as various studies have shown that it can be modulated with small molecules. For example, one study shown that the neurotransmitter dopamine can inhibit the activity of SPRR1b and increase the release of neurotransmitters such as synaptophysin. Additionally, another study shown that SPRR1b can be modulated with small molecules such as RNA interference, which can target specific regions of the gene for knockdown.

In conclusion, SPRR1b is a protein that is involved in the regulation of synaptic plasticity and has been shown to play a role in various neurological and psychiatric disorders. Its potential as a drug target and biomarker makes it an attractive target for further research and development of new treatments for these disorders.

Protein Name: Small Proline Rich Protein 1B

Functions: Cross-linked envelope protein of keratinocytes. It is a keratinocyte protein that first appears in the cell cytosol, but ultimately becomes cross-linked to membrane proteins by transglutaminase. All that results in the formation of an insoluble envelope beneath the plasma membrane. Can function as both amine donor and acceptor in transglutaminase-mediated cross-linkage

The "SPRR1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPRR1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets